{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Multiple references to the Schedule of Activities (SoA) in Section 1.3 and Table 1 for study procedures and timing."
      },
      {
        "id": "ref_2",
        "name": "Dose Modification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Cross-reference to dose modification or discontinuation criteria for managing adverse events like elevated transaminases."
      },
      {
        "id": "ref_3",
        "name": "Study Assessments Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from the amendment summary regarding clarification of study procedures for US sites."
      },
      {
        "id": "ref_4",
        "name": "Adverse Event Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Multiple references to procedures for recording, evaluating, and reporting AEs and SAEs."
      },
      {
        "id": "ref_5",
        "name": "Contraceptive Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference to appropriate contraceptive methods for study participants."
      },
      {
        "id": "ref_6",
        "name": "COVID-19 Vaccine Risk Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference to potential risks and mitigation measures due to COVID-19 vaccine."
      },
      {
        "id": "ref_7",
        "name": "Adaptive Features Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference to Table 4 describing adaptive design features of the study."
      },
      {
        "id": "ref_8",
        "name": "Dose Modification Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference to Table 7 for criteria on when a dose should be decreased or interrupted."
      },
      {
        "id": "ref_9",
        "name": "Exclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Lifestyle Considerations regarding blood donation restriction prior to screening."
      },
      {
        "id": "ref_10",
        "name": "Discontinuation Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference to Section 7 for QTc withdrawal criteria and participant discontinuation."
      },
      {
        "id": "ref_11",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to the list of clinical laboratory tests to be performed."
      },
      {
        "id": "ref_12",
        "name": "Lost to Follow-up Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference to the definition of 'lost to follow-up' for SAEs."
      },
      {
        "id": "ref_13",
        "name": "Genetic Testing Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference indicating that retained samples will not be used for genetic testing."
      },
      {
        "id": "ref_14",
        "name": "Copper and Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference to details of copper and molybdenum measured in food, drink, urine, and feces."
      },
      {
        "id": "ref_15",
        "name": "Pharmacodynamics/Biomarkers Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.6",
        "sectionTitle": "Pharmacodynamics",
        "description": "Reference to details of pharmacodynamic and biomarker assessments."
      },
      {
        "id": "ref_16",
        "name": "Analysis Populations Table Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference to Table 8 which defines the population sets for analysis."
      },
      {
        "id": "ref_17",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "N/A",
        "sectionTitle": "Investigator's Brochure (IB)",
        "description": "Multiple references to the external Investigator's Brochure for risk information and nonclinical data."
      },
      {
        "id": "ref_18",
        "name": "Study Schematic Figure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Figure 1",
        "sectionTitle": "Study Schematic",
        "description": "Reference to the study schematic figure."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Addition of text to the footnote to state that procedures specific to screening sites (only in the US) detailed in Section 8",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_5",
        "text": "Note: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4. Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original Protocol Approval"
      },
      {
        "id": "ver_2",
        "versionNumber": "1.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Protocol Amendment 1 Approval",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_3",
        "versionNumber": "2.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Protocol Amendment 2 Approval",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "3.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Protocol Amendment 3 Approval",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_5",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Protocol Amendment 3.1 (US) Approval",
        "amendmentNumber": "Amendment 3.1 (US)"
      }
    ],
    "summary": {
      "referenceCount": 18,
      "annotationCount": 5,
      "versionCount": 5
    }
  }
}